China’s Kelun-Biotech Strikes $1.33 Billion Cancer Therapy Licensing Deal with Crescent Biopharma
China’s Sichuan Kelun-Biotech Biopharmaceutical has entered a major licensing agreement with U.S.-based Crescent Biopharma, granting the company global (ex-China) rights to develop and commercialise its experimental cancer therapy, SKB105. The deal, announced Thursday in Shanghai, includes an $80 million upfront…